GPC2 CAR T cells
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Refractory Neuroblastoma
Conditions
Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma, Retinoblastoma, Metastatic Retinoblastoma
Trial Timeline
May 23, 2023 → Jan 30, 2030
NCT ID
NCT05650749About GPC2 CAR T cells
GPC2 CAR T cells is a phase 1 stage product being developed by Gilead Sciences for Refractory Neuroblastoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05650749. Target conditions include Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma.
What happened to similar drugs?
3 of 20 similar drugs in Refractory Neuroblastoma were approved
Approved (3) Terminated (1) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05650749 | Phase 1 | Recruiting |
Competing Products
20 competing products in Refractory Neuroblastoma